Skip to main content
Industry News
FDA clears IND for Kleo's multiple myeloma combo drug

The FDA has cleared Kleo Pharmaceuticals' investigational new drug application for its candidate KP1237, combined with autologous natural killer cells, as a treatment for multiple myeloma in patients who have already undergone hematopoietic stem cell transplantation. The clearance allows Kleo to advance its planned trial, with enrollment slated to start in the first half of this year and topline data expected by the second half of 2021.

Full Story: